- ROSIGLITAZONE NEW ENGLAND JOURNAL OF MEDICINE TRIAL
- ROSIGLITAZONE NEW ENGLAND JOURNAL OF MEDICINE PROFESSIONAL
Lancet 2007 370(9593):1129–36.The most detailed look ever at data for rosiglitazone, the diabetes drug marketed by GlaxoSmithKline (GSK) as Avandia, shows the one-time blockbuster significantly raises the overall risk of heart problems or cardiovascular death, calling attention to the need for more transparency in data collection. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. Grading quality of evidence and strength of recommendations. Methods to increase response rates to postal questionnaires.
ROSIGLITAZONE NEW ENGLAND JOURNAL OF MEDICINE PROFESSIONAL
Physicians’ knowledge, attitudes and professional use of RCTs and meta-analyses: a cross-sectional survey. Boston (MA): Little, Brown and Company 1991.ġ8. Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd edition.
Regulatory action on rosiglitazone by the U.S. London, United Kingdom: The Agency 2010 96996.pdf.ġ6. Anti-diabetes medication to be taken off the market. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five riskwarning events. Starner CI, Schafer JA, Heaton AH, et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Rosiglitazone for type 2 diabetes mellitus. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. Lipscombe LL, Gomes T, Levesque LE, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. Juurlink DN, Gomes T, Lipscombe LL, et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
ROSIGLITAZONE NEW ENGLAND JOURNAL OF MEDICINE TRIAL
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Dormandy JA, Charbonnel B, Eckland DJ, et al. Thiazolidinedione use and bone loss in older diabetic adults. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. Metabolic and additional vascular effects of thiazolidinediones. National trends in treatment of type 2 diabetes mellitus, 1994–2007. Alexander GC, Sehgal NL, Moloney RM, et al.
0 kommentar(er)
